Panacea Venture

James Huang spent 20+ years as a big-pharma and biotech operator, coaches companies on execution and scaling, specializes in U.S.–China cross-border biotech, and often serves as executive chairman or CEO.

Previously Portfolio Manager of Ample Plus, a healthcare crossover fund, and worked at RA Capital covering CNS, hepatology and oncology. Holds an MD/MBA from Tufts University School of Medicine.

Head of Healthcare Investment at VMS Group and previously Head of China Healthcare equity research at Barclays Capital. Holds an MBA from INSEAD and engineering degrees from Cornell.

Founding Managing Partner of BE Health and CIO of Show Chwan Health Care System. Holds an EMBA (Columbia, LBS, HKU) and advanced degrees in biomedical informatics and electrical engineering.

Former CEO of ImaginAb, CEO and Chairman of Immune Targeting Systems, and Managing Director at Burrill & Company. Holds a PhD in immunology from the University of Wisconsin with postdoctoral work at Stanford.

Founder and former CEO of ASLAN Pharmaceuticals, previously Head of Asia Healthcare at Bank of America Merrill Lynch and Regional BD Director APAC at AstraZeneca. Holds a PhD and MA in molecular biology from Cambridge and an MBA from London Business School.

Previously a partner at 6 Dimensions Capital/WuXi Healthcare Ventures, co-head of pharma/biotech at CBC Group and Principal at Decheng Capital. Holds a BA from Columbia, an MD from Stanford and an MBA from Harvard.

Previously a partner and Head of Healthcare Investments at 7G Bioventures, with roles at AGIC Capital, Milestone Capital and JJDC. Holds a PhD in neuroscience from Columbia and a BS from the University of Science and Technology of China.

Previously a Director at KPCB with prior roles at Zimmer Biomet and Hutchison MediPharma. Holds an MBA from Duke, an MA in biotechnology from Columbia and a BS from the University of Texas at Austin.

Previously a partner at Kairos, InnoPinnacle and Pagoda Capital. Holds a PhD from Dartmouth and MS/BS degrees in biomedical engineering from Tianjin University.

Recipient of the FDA/CBER Scientific Achievement Award and a former CBER FDA reviewer in gene and cell therapy, with prior roles at Sangamo, Amgen and Amsterdam Molecular Therapeutics. Holds an MD from Albert Einstein College of Medicine.

Previously SVP of Global Regulatory, Safety & Biometrics at BMS, with roles at Novartis and Hoffmann La Roche. Serves on the boards of Centessa and Compugen. Holds a BS and PhD in biology and biochemistry from the University of Nijmegen.

Previously VP Marketing at Braeburn with senior leadership roles at GlaxoSmithKline, Teva and Anesiva. Holds a BA in communication from Villanova.

Previously Senior VP of Sales and Marketing at Anesiva with senior roles at Braeburn, Teva and GlaxoSmithKline. Holds a BS in food marketing from Saint Joseph's University.

Previously at Oracle Partners, Apelles, Argenis and Amgen. Emeritus Trustee at the University of Pennsylvania Health System. Holds an MD and PhD from the University of Pennsylvania.

Chief Central Superintendent of Show Chwan Healthcare System and Director of IRCAD Taiwan/AITS, and Partner at BE Health. Holds an MD from Tulane, a PhD from Tokyo Women's Medical University and an MPH from Tulane.

Previously an attorney at Ropes & Gray LLP. Holds an LLM from the University of Pennsylvania and an LLM/LLB from Shanghai University of International Business and Economics.

Previously President and Chief Strategy Officer of LianBio and Managing Director of cross-border investment banking at China Renaissance, with prior roles at Pfizer, Bay City Capital and Delphi Ventures. Holds an MD from Harvard Medical School and a BA from Princeton.

Has 20 years of private markets experience as investor and fundraiser, previously Principal at Blue Owl Capital and Director at Credit Suisse PFG, with prior roles at PingAn Group, Nanshan Life and Schroeder Adveq. Holds a BS in business management from Indiana University.